Adjusted daily closes · 252 observations · as of Nov 6, 2026
Historical data, not a forecast
1 month
+11.7%
3 months
-1.0%
6 months
-2.4%
1 year
+12.8%
Year to date
+17.6%
52-week range
$15.74 – $21.60
Fundamental snapshot
Latest reported period: Sep 30, 2026
Sharadar reported data
Market cap
$6.5B
P/E
-144.7
P/B
1.6
P/S
5.7
Revenue
$1.13B
Net income
-$44.93M
Diluted EPS
-0.14
Gross margin
63.60%
Net margin
-4.00%
Return on equity
-1.00%
Total debt
$4.49B
Cash
$17.5M
Free cash flow
$846.94M
Latest eight reported quarters
Reported quarterly values, newest first
Period
Revenue
Net income
Gross margin
Net margin
Free cash flow
Sep 30, 2026
$286.64M
-$15.76M
64.30%
-5.50%
$88.5M
Jun 30, 2026
$281.85M
-$43.51M
64.90%
-15.40%
$82.33M
Mar 31, 2026
$278.99M
-$56K
64.10%
0.00%
$18.93M
Dec 31, 2025
$286.3M
$14.39M
61.30%
5.00%
$657.19M
Sep 30, 2025
$297.77M
-$57.74M
61.90%
-19.40%
$343.8M
Jun 30, 2025
$297.5M
-$157.85M
63.10%
-53.10%
$123.25M
Mar 31, 2025
$298.98M
-$44.87M
61.50%
-15.00%
-$5.4M
Dec 31, 2024
$309.77M
-$106.85M
63.10%
-34.50%
$554.91M
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Hormel Foods Corporation has appointed Joe O’Connor as group vice president, enterprise performance, effective October 26, 2026. In this new role, O'Connor will oversee efforts to enhance decision-making, planning processes, and long-term business performance across all business units and functions. With over two decades at Hormel Foods, O'Connor brings extensive experience from various leadership positions in sales, marketing, category management, and general management, most recently serving as vice president, emerging brands.
Family trusts linked to Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), sold 1,723 common shares on November 4, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales occurred at weighted-average prices ranging from $610.2928 to $613.1350 per share. This trading plan is scheduled to continue until the earlier of exercising 1,734,410 stock options or December 31, 2026.
Danaher (DHR) has seen its stock fair value increase due to analysts raising price targets, with several now between US$260 and US$275. This optimism is driven by the company's 2027 core growth projections, Q3 2026 performance, and potential for improved margins and organic growth. The revised fair value estimate for Danaher has moved from US$244.14 to US$259.90.
Danaher director Alan G. Spoon acquired 193 phantom shares on October 30, 2026, under the company's Non-Employee Directors Deferred Compensation Plan. These phantom shares, which are equivalent to common stock upon distribution, were priced at Danaher's closing price of $232.23 per share on the transaction date. This acquisition increased Spoon's total holdings to 31,236 phantom shares, in which he is fully vested.
Danaher Corporation director Elias A. Zerhouni was awarded 199 phantom shares on October 30, 2026, priced at $232.23 per share, increasing his total holdings to 18,908 phantom shares. These phantom shares, deferred under the Non-Employee Directors Deferred Compensation Plan, are fully vested and convert into Danaher common stock on a one-for-one basis upon distribution.
Wall Street Zen upgraded Danaher (DHR) stock from Hold to Buy on October 26, contributing to a bullish analyst view. This upgrade, along with several price target increases from firms like TD Cowen and JPMorgan, followed Danaher's stronger-than-expected third-quarter results. While respiratory demand remains a headwind, the company improved its 2026 adjusted earnings outlook and showed stronger execution in life sciences, biotechnology, and diagnostics.
Marvell's reported bid for Lumentum is sending shockwaves through the optical networking sector, but the company with the most to gain from this deal may not be either party sitting at the negotiating table.